Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caduet in Untreated Hypertensive and Dyslipidemic Subjects
NCT00332761Phase 4Completed
- Sponsor
- Viatris
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of amlodipine in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Viatris. Primary endpoint: Percentage of subjects achieving both blood pressure goal (<140/90 mmHg) and LDL-C goal (<100 mg/dL) at 4 weeks. Started Jun 2006; status: completed.
02
Drugs
amlodipine
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT00332761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332761.